Evidence map›Paper›PMID 41219650›Full record

ArticleIntensive care medicine experimental2025

Unravelling the complex inflammatory landscape of COVID-19 infection: a pathway to biomarkers identification in infection-associated delirium in the ICU.

Tristan Born, Matthieu Perreau, Pierre-Paul Axisa, Craig Fenwick, Andrea Pinto, Nawfel Ben-Hamouda, Andrea O Rossetti, Renaud Du Pasquier, Jean-Daniel Chiche, Raphaël Bernard-Valnet

Abstract read
In one paragraph

Article in Intensive care medicine experimental, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tristan BornService of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois (CHUV)) and University of Lausanne (UNIL), Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Matthieu PerreauService of Immunology and Allergy, Department of Medicine, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois) and University of Lausanne, Lausanne, Switzerland.
Pierre-Paul AxisaCancer Research Center of Toulouse (CRCT), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université Toulouse III-Paul Sabatier (UPS), Toulouse, France.
Craig FenwickService of Immunology and Allergy, Department of Medicine, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois) and University of Lausanne, Lausanne, Switzerland.
Andrea PintoDepartment of Computer Science (INFK), ETH Zurich, Zurich, Switzerland.
Nawfel Ben-HamoudaDepartment of Intensive Care Medicine, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois) and University of Lausanne, Lausanne, Switzerland.
Andrea O RossettiService of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois (CHUV)) and University of Lausanne (UNIL), Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Renaud Du PasquierService of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois (CHUV)) and University of Lausanne (UNIL), Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Jean-Daniel ChicheDepartment of Intensive Care Medicine, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois) and University of Lausanne, Lausanne, Switzerland.
Raphaël Bernard-ValnetService of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois (CHUV)) and University of Lausanne (UNIL), Rue du Bugnon 46, 1011, Lausanne, Switzerland. Raphael.bernard-valnet@chuv.ch.ORCID http://orcid.org/0000-0001-7447-344X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDelirium is a serious complication in patients with COVID-19-related acute respiratory distress syndrome (ARDS) admitted to the intensive care unit (ICU). Although numerous clinical risk factors have been identified, the immunologic pathways underlying delirium remain unclear. In this retrospective cohort study, we investigated high-dimensional immune signatures in ICU patients to delineate peripheral immune markers associated with delirium. We also explored machine learning (ML) approaches to enhance biomarker discovery and strengthen predictive modelling through synthetic data generation.

methodsWe studied a cohort of 62 COVID-19 ARDS patients admitted to the ICU at Lausanne University Hospital, Switzerland. The primary analysis compared patients within this cohort who developed delirium (n = 39) to those who remained delirium-free (n = 23). As a baseline for disease severity, we also compared the ICU cohort to 55 non-ICU COVID-19 patients and 450 healthy individuals. We performed high-dimensional immunophenotyping of cytokines, chemokines, and growth factors using multiplex beads assay, along with immune cell profiling via mass cytometry (CyTOF). Ridge regression has been employed to build classification models. We also generated synthetic samples using beta-variational autoencoders to improve sample size and subsequently model stability.

resultsDelirious patients exhibited a distinctive immune signature, including elevated CXCL1, CCL11, CXCL13, HGF, and VEGF-A, coupled with reduced IL-1α, IL-21, and IL-22. Alterations in immune cell populations featured increased exhausted B cells and decreases in CXCR3 + CD4 + T cells, IgM + unswitched memory B cells, and HLA-DR + activated T cells. Leveraging these high-dimensional data, we trained ridge regression models to predict delirium. Incorporating synthetic data helped stabilize the models with a best-performing model achieving an area under the curve (AUC) of 0.95, with high sensitivity (93%) and specificity (86%), based on 12 identified markers.

conclusionOur findings demonstrate a distinct immune profile linked to ICU delirium and illustrate how ML can enhance biomarker discovery. Further prospective validation may refine these markers and guide precision-targeted interventions for mitigating delirium in critically ill populations.

Identifiers

PMID41219650
PMCPMC12605842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.